Neurocrine Biosciences (NBIX) Current Assets (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Current Assets for 17 consecutive years, with $1.6 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets fell 6.37% year-over-year to $1.6 billion; the trailing twelve-month figure through Jun 2026 stood at $1.6 billion (down 6.37% YoY), and the FY2025 full-year result was $2.5 billion, up 46.27% from the prior year.
• Current Assets retreated to $1.6 billion in Q2 2026 per NBIX's latest filing, from $2.4 billion in the prior quarter.
• Across five years, Current Assets topped out at $2.5 billion in Q4 2025 and bottomed at $1.0 billion in Q1 2022.
• Historically, Current Assets has averaged $1.7 billion across 5 years, with a median of $1.6 billion in 2023.
• The sharpest annual moves came in 2022 and 2025: Current Assets surged 49.41% in 2022, then declined 8.95% in 2025.
• Over 5 years, Current Assets stood at $1.5 billion in 2022, then rose by 10.56% to $1.6 billion in 2023, then grew by 7.32% to $1.7 billion in 2024, then jumped by 46.27% to $2.5 billion in 2025, then plunged by 35.09% to $1.6 billion in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $1.6 billion, $2.4 billion, and $2.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.